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ABSTRACT The enediyne family of natural products has had a profound impact on modern chemistry, biology, and medicine,
and yet only 11 enediynes have been structurally characterized to date. Here we report a genome survey of 3,400 actinomycetes,
identifying 81 strains that harbor genes encoding the enediyne polyketide synthase cassettes that could be grouped into 28 dis-
tinct clades based on phylogenetic analysis. Genome sequencing of 31 representative strains confirmed that each clade harbors a
distinct enediyne biosynthetic gene cluster. A genome neighborhood network allows prediction of new structural features and
biosynthetic insights that could be exploited for enediyne discovery. We confirmed one clade as new C-1027 producers, with a
significantly higher C-1027 titer than the original producer, and discovered a new family of enediyne natural products, the
tiancimycins (TNMs), that exhibit potent cytotoxicity against a broad spectrum of cancer cell lines. Our results demonstrate the
feasibility of rapid discovery of new enediynes from a large strain collection.
IMPORTANCE Recent advances in microbial genomics clearly revealed that the biosynthetic potential of soil actinomycetes to pro-
duce enediynes is underappreciated. A great challenge is to develop innovative methods to discover new enediynes and produce
them in sufficient quantities for chemical, biological, and clinical investigations. This work demonstrated the feasibility of rapid
discovery of new enediynes from a large strain collection. The new C-1027 producers, with a significantly higher C-1027 titer
than the original producer, will impact the practical supply of this important drug lead. The TNMs, with their extremely potent
cytotoxicity against various cancer cells and their rapid and complete cancer cell killing characteristics, in comparison with the
payloads used in FDA-approved antibody-drug conjugates (ADCs), are poised to be exploited as payload candidates for the next
generation of anticancer ADCs. Follow-up studies on the other identified hits promise the discovery of new enediynes, radically
expanding the chemical space for the enediyne family.
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Natural products offer unmatched chemical and structural di-versity compared to any other small-molecule families. They
continue to inspire novel chemistry, enzymology, and biology in-
vestigations and remain the best sources of drugs and drug leads
(1). The enediynes represent one of the most fascinating families
of natural products for their unprecedented molecular architec-
ture and extraordinary biological activities. Since the neocarzinos-
tatin (NCS) chromophore structure was first unveiled in 1985 (2),
the enediyne family has grown steadily but remains very small,
with only 11 structurally characterized members and 4 additional
members isolated in their cycloaromatized form known to date.
Classified into two subcategories according to the size of the
enediyne core structures (3–7), members of the 9-membered
enediyne subcategory include NCS, C-1027, kedarcidin (KED),
maduropeptin (MDP), N1999A2, the sporolides (SPO), the cya-
nosporasides (CYA and CYN), and the fijiolides, with the latter
four isolated in cycloaromatized form (see Fig. S1A in the supple-
mentalmaterial).Members of the 10-membered enediyne subcat-
egory include the calicheamicins (CAL), the esperamicins (ESP),
dynemicin (DYN), namenamicin, shishijimicin, and uncialamy-
cin (UCM) (Fig. S1B).
The enediynes have had a profound impact on modern chem-
istry, biology, and medicine (3, 4, 7). All enediynes contain a unit
consisting of two acetylenic groups conjugated to a double bond
or an incipient double bond within the 9- or 10-membered car-
bocycle (Fig. S1A and B). As a consequence of this structural fea-
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ture, the enediynes share amode of action—electronic rearrange-
ment of the enediyne carbocycle produces a transient benzenoid
diradical. When positioned within the minor groove of DNA, the
diradical abstracts hydrogen atoms from the deoxyribose back-
bone of duplex DNA; the DNA-centered radicals can then cause
interstrand cross-links (ICLs) or react with molecular oxygen,
leading ultimately to DNA double-strand breaks (DSBs), or both
(3, 4, 7, 8). With their exquisite mode of action and their extraor-
dinary cytotoxicity, the enediynes have been successfully trans-
lated into clinical drugs. It is remarkable that, among the 11
enediynes known to date, 2 [NCS as poly(styrene-comaleic acid)-
conjugated NCS (SMANCS) and CAL as gemtuzumab ozogami-
cin (Mylotarg)] have been developed into marketed drugs, 1 (C-
1027) is in clinical trials, and another (UCM) is in preclinical
studies, representing an astonishing and remarkable ~35% suc-
cess rate with the enediyne class of natural products (3–7). A great
challenge is that of developing innovative methods to discover
new enediynes and producing them in sufficient quantities for
chemical, biological, and clinical investigations.
Here we report strain prioritization and genome mining for
enediyne natural products from the actinomycetes strain collec-
tion at the Scripps Research Institute (TSRI). By surveying 3,400
strains, we identified 81 potential producers, and genome se-
quencing of 31 representatives revealed at least 28 distinct
enediyne biosynthetic gene clusters. We constructed an enediyne
genome neighborhood network (GNN) to facilitate gene cluster
annotation and to predict new structural features, thereby further
streamlining the discovery of new enediyne natural products. To
demonstrate the feasibility of our approach in rapidly discovering
new enediynes from a large strain collection, we characterized a
newC-1027 producer with a significantly higher C-1027 titer than
the original Streptomyces globisporus producer (9, 10) and discov-
ered the tiancimycins (TNMs), new enediyne natural products
that exhibit potent cytotoxicity against a broad spectrumof cancer
cell lines and kill selected cancer cellsmore rapidly and completely
than the payloads used in FDA-approved antibody (Ab)-drug
conjugates (ADCs). Production of TNMs in sufficient quantities
by microbial fermentation and manipulation of TNM biosynthe-
sis for engineering new analogues were also demonstrated.
RESULTS AND DISCUSSION
Genome survey of 3,400 actinomycetes for the enediyne
polyketide synthase gene cassette identifying 81 potential
enediyne producers that could be grouped into 28 distinct
clades. Since the cloning of the first 9-membered (C-1027) (11)
and 10-membered (CAL) (12) enediyne biosynthetic gene clusters
in 2002, three additional 9-membered (NCS, MDP, and KED)
(13–15) and two additional 10-membered (DYN and ESP [par-
tial]) (16, 17) enediyne gene clusters, as well as the three clusters
encoding the biosynthesis of SPO (18), CYA (19), and CYN (19),
have been characterized. Comparative analysis of the 10 gene clus-
ters revealed a set of 5 genes common to all enediynes, i.e., the
enediyne polyketide synthase (PKS) gene cassette consisting of E3,
E4, E5, E, and E10 (E3/E4/E5/E/E10) (Fig. S2A) (17, 20–22); no
apparent conservation was observed beyond the enediyne PKS
gene cassettes, accounting for the structural diversity characteris-
tic for the periphery moieties of the enediynes (Fig. S1A and B).
The remarkable sequence homology prompted us to select genes
within the enediyne PKS cassettes as probes to survey genomes for
the presence of enediyne biosynthetic machinery. This was vali-
dated recently by a virtual survey of all bacterial genomes available
in public databases, revealing the rich potential of biosynthesis of
enediynes by actinomycetes (Fig. S2B and C) (5, 6).
Inspired by the accuracy and specificity of the virtual screening,
we adapted our recently developed high-throughput real-time
PCRmethod (23) to survey the TSRI actinomycetes collection for
the enediyne PKS gene cassettes to identify new enediyne produc-
ers (Fig. 1A). Two sets of PCR primers were designed to specifi-
cally target E5/E or E/E10 (Fig. 1B). Hits identified by both sets of
the primers featured the enediyne PKS gene cassettes with E5/E/
E10 clustered together, while hits identified by only one of the two
sets of primers featured an enediyne PKS gene cassette with either
E5 or E10 separate from the E gene (Fig. 1B). By real-time PCR in
a 384-well plate format, specific PCR products were rapidly iden-
tified, in a high-throughput manner, by melting curve analysis
and confirmed by gel electrophoresis and DNA sequencing
(Fig. 1C). From 3,400 representative strains, 81 distinct enediyne
producers were identified on the basis of the identity of the
enediyne PKS gene cassettes (i.e., E5, E10, and a 1-kb internal
fragment of E), taxonomy, and geographic locations where the
strains were isolated (Fig. 1B to E). Phylogenetic analysis of the 81
new enediyne PKS cassettes, with the known enediyne PKS cas-
settes as controls, was carried out using the translated 1-kb inter-
nal fragment of E. While each of the enediyne PKS cassettes is
unique, the phylogenetic tree of the 81 new enediyne PKS cassettes
subjected to 90% amino acid identity cutoff collapsed into 28
distinct clades (the pairwise comparison of the known enediyne
PKS cassettes revealed amino acid sequence identities ranging
from 33% to 69%) (Fig. 2A). It is therefore very significant that 27
of the 28 clades are distinct from the known enediyne PKS cas-
settes, indicative of novel enediynes. The CB02366 group forms a
clade with the C-1027 enediyne PKS cassette (11), suggesting that
these hits potentially represent new C-1027 producers (Fig. 2A,
section A).
Genome sequencing of 31 representative hits from the 28
clades confirmed that they all contain an enediyne gene cluster
and therefore are true enediyne producers (Fig. 2). Significantly,
hits from different clades yielded distinct enediyne gene clusters,
while hits from the same clade afforded highly homologous gene
clusters, as exemplified by TSRI0395, TSRI0261, CB02115, and
CB00072 (Fig. 2A, section B) (only the cluster from CB00072 is
shown; Fig. 2C). These findings support the proposal of using the
enediyne PKS cassette clades to further prioritize the hits and
streamline enediyne natural-product dereplication.
Discovery of Streptomyces sp. strain CB02366 as a new
C-1027 producer with a significantly higher titer than the orig-
inal producer. C-1027 was originally isolated from Streptomyces
globisporus in 1993 (10). C-1027 has been in clinical development
as an antibody-drug conjugate (ADC) for hepatoma (24, 25). We
have been studying C-1027 biosynthesis in S. globisporus as a
model for enediyne biosynthesis and engineering (7, 11, 20, 22,
26). To confirm the four hits that form a clade with the C-1027
enediyne PKS cassette as alternative C-1027 producers (Fig. 2A,
section A), we sequenced the genome of Streptomyces sp. strain
CB02366, a representative from the clade, and indeed revealed a
C-1027 biosynthetic gene cluster (Fig. 3A). We subsequently iso-
lated C-1027 from Streptomyces sp. strain CB02366 and generated
pksE mutant strain SB1036 (Fig. S3; see also Table S1 in the
supplemental material), which has completely lost its ability to
produce C-1027, thereby confirming that the cloned gene cluster
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encodes the C-1027 biosynthetic machinery (Fig. 3B and C). In-
terestingly, CB02366, isolated from a soil sample collected in
Dubai, United Arab Emirates, is classified as a Streptomyces griseus
species (Table S2), but the original C-1027 producer, isolated
from a soil sample collected in Qianjiang county, Hubei Province,
China, is known as Streptomyces globisporus (27). And yet the two
C-1027 clusters are highly homologous (with identical genetic or-
ganizations and ~90%/94% identity of DNA/amino acid se-
quences) (Fig. 3A and Table S3). The finding of Streptomyces sp.
strain CB02366 as an alternative C-1027 producer is significant
because C-1027 had not been rediscovered since it was first iso-
lated in 1993 (10). Remarkably, Streptomyces sp. strain CB02366
produces the C-1027 chromoprotein with a titer of ~750mg/liter,
which is minimally 10-fold higher than that produced by the orig-
inal S. globisporus wild-type strain at ~74 mg/liter (calculated on
the basis of 5.5 mg/liter of the C-1027 chromophore as deter-
mined by high-performance liquid chromatography [HPLC]
analysis) (Fig. 3B) (9). Multiple producers (for either known or
new enediynes) with various growth characteristics and levels of
genetic amenability also present new opportunities for yield im-
FIG 1 Strain prioritization and genome mining for enediyne natural products. (A) A high-throughput method to survey the enediyne biosynthetic machinery
in a strain collection and prioritize the hits for new enediyne natural-product discovery: (i) genome survey of 3,400 representative strains from the TSRI
actinomycetes collection identifying 81 novel enediyne producers; (ii) genome sequencing of 31 representative producers yielding 28 distinct enediyne biosyn-
thetic gene clusters; (iii) construction of an enediyne GNN unveiling new insights for enediyne biosynthesis and structural novelty; and (iv) fermentation
optimization and production, isolation, and structural elucidation affording the new enediyne natural products. (B) Design of PCR primers for enediyne PKS
gene cassette, targeting E5/E or E/E10, and the primers for the 1-kb internal fragment of E. (C) Representative melting curve analysis in real-time PCR in a
384-well plate format, as exemplified by using E/E5 or E10/E primers, with each of the peaks indicating a specific product. Solid lines with open circles represent
the positive controls (genomic DNAs of the C-1027 producer S. globisporus and the KED producer Streptomyces sp. strain ATCC 53650 were used as positive
controls for E/E5 and E10/E amplification, respectively), and dashed lines represent the negative controls with no-template DNA. Insets show PCR products of
the hits that were analyzed by agarose gel electrophoresis and confirmed by DNA sequencing. (D) Geographic distribution of the 81 new enediyne producers
identified (see Table S2 for details). Numbers in parentheses are the numbers of new enediyne producers isolated from each of the clades. (E) Taxonomic
distribution of the 81 newly identified enediyne producers in the culture collection, with approximately 88% of them belonging to the Streptomyces genus,
ensuring that the expedient genetic tools developed in the past two decades for Streptomyces will be readily available to manipulate the enediyne biosynthetic
machinery in these producers for production, titer improvement, and structural diversity.
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provement, structural diversity, or both by applying metabolic
pathway engineering strategies and methods (1, 28). The fact that
most of the new enediyne producers identified in this study are
Streptomyces species (Fig. 1E) ensures that the expedient recom-
binant DNA technologies and genetic tools available can be read-
ily adopted for these experiments.
An enediyne GNN facilitating gene cluster annotation and
predicting new structural features. For the other 27 clades, ge-
nome sequencing of representative hits unveiled gene clusters that
are distinct from all enediyne biosynthetic gene clusters known to
date (Fig. 2), indicative of novel enediyne natural products. GNNs
have recently emerged as a component of a powerful bioinformat-
FIG2 A genome survey of 3,400 strains from the TSRI actinomycetes collection, identifying 81 enediyne producers. (A) Phylogenetic analysis of the 81 enediyne
gene clusters, based on the translated 1-kb internal fragment of the E genes, in comparison with the 11 known enediyne producers (red), affording 28 distinct
clades upon employing a 90% amino acid identity cutoff value. Numbers in parentheses are the hits identified from each of the clades. The clades of alternative
C-1027 producers (section A), multiple producers sequenced with highly homologous enediyne gene clusters (section B), and the TNM producer Streptomyces
sp. strain CB03234 (section C) are highlighted. (B) The 10 enediyne biosynthetic gene clusters known previously and the ucm biosynthetic gene cluster
characterized in this study (see Table S3 for detailed annotation). (C) The 28 distinct enediyne gene clusters identified upon genome sequencing of 31
representative hits from the 28 clades (see Tables S3 and S4 for detailed annotation). Genes are color-coded based on GNN annotation (see Fig. 4).
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ics strategy to predict enzyme functions on a large scale based on
their genomic context (29, 30). Given the high complexity of
enediyne gene clusters (often spanning 80 kb to 120 kb of DNA
and consisting of 50 to 75 open reading frames [ORFs]), the large
number of functionally unassigned proteins in these gene clusters,
and, most importantly, the desire to compare the new enediyne
gene clusters to the knownones, we constructed an enediyneGNN
to quickly and accurately analyze the new enediyne gene clusters.
The enediyne GNN (Fig. 4) included all known enediyne gene
clusters (Fig. 2B) and the 31 new enediyne gene clusters (i.e., the
28 distinct gene clusters and the 3 homologous gene clusters from
the same clade of CB00072 [Fig. 2A, section B]) (Fig. 2C). The
newly discovered enediyne biosynthetic gene clusters are diverse
and rich in new chemistry (Fig. 4), featuring many enzyme fami-
lies that are different from those encoded by the known enediyne
gene clusters or are functionally unknown (Fig. 4C and D). Close
examination of the GNN unveiled many new insights that could
be exploited to predict novel structural features and guide exper-
imental designs to discover new enediyne natural products.
The 28 distinct new gene clusters can be divided into two
groups using our recently reported method to predict 9-membered
or 10-membered enediynes based on the exclusive presence of E2
or R3 genes, respectively (5)—21 clusters expected to encode the
production of 9-membered enediynes and 7 clusters expected to
encode the production of 10-membered enediynes (Fig. 4B and
Table S2). Among the predicted 9-membered producers (Ta-
ble S2), seven contain apoprotein genes (encoding CB01883,
CB02009, CB02130, CB02261, CB02366, CB02400, andCB03578)
(also see Table S4), andmany strains share commongenes respon-
sible for the biosynthesis of peripheral moieties, such as –amino
acids (CB00455, CB01883, CB02009, CB02130, CB02261, and
CB02414), amino sugar (CB01580, CB02414, CB02460, and
TSRI0369), and benzoxazolinate (CB02261, CB02130, CB02009,
CB01883, CB00455, and CB02400) (Table S4). Besides these
known moieties, several predicted 9-membered enediyne gene
clusters contain genes encoding the biosynthesis of unknown
moieties. For example, the enediyne gene cluster from CB03578
encodes enzymes for tryptophan degradation (making those
genes unique among enediyne biosynthetic gene clusters), meth-
yltransferases, and corresponding activation and condensing en-
zymes, implying the presence of an anthranilic acid-like periph-
eral moiety (Fig. 4E and Table S4).
Among the strains harboring predicted 10-membered enediyne
biosynthetic gene clusters (Table S2), one strain (TSRI0369) is pro-
posed to produce an enediyne compound structurally similar to
CAL (Table S4) and another one (CB03234) (Table S3) shares
many homologous genes with the DYN biosynthetic gene cluster
from Micromonospora chersina and the UCM gene cluster from
S. uncialis, while the other five gene clusters (CB00072, TSRI0455,
CB03911, CB02488, and CB01950) are fundamentally different
from the reported 10-membered enediyne biosynthetic gene clus-
ters (also see Table S4), implying that they might produce new
families of 10-membered enediynes. This notion is highlighted by
results seen with the gene cluster from CB03911, which possesses
putative 10-membered enediyne resistance genes, shikimate path-
way enzyme genes, and several singletons (Fig. 4F and Table S4).
Chorismate metabolism has been seen in 9-membered enediyne
biosynthesis (e.g., benzoxazolinate in C-1027) but was not seen in
suspected 10-membered enediyne biosynthesis until now (4, 7,
11).
Tiancimycins (TNMs) from Streptomyces sp. strainCB03234
demonstrating our approach in rapidly discovering new
enediynes. We noticed that Streptomyces sp. strain CB03234 is
clustered together with the UCM (31), ESP (32), and DYN (33)
producers upon phylogenetic analysis of their enediyne PKS cas-
settes (Fig. 2A, section C), suggesting that CB03234 might pro-
duce a new 10-membered enediyne. The dyn biosynthetic gene
cluster was previously cloned fromM. chersina (Fig. 5A) (16), but
FIG 3 Characterization of Streptomyces sp. strain CB02366 as an alternative C-1027 producer. (A) Genetic organization of the C-1027 gene cluster from
CB02366 (see Table S3). (B) HPLC analysis of fermentations of the Streptomyces sp. strain CB02366 wild type (II) and SB1036 (i.e.,pksE) mutant (III), with the
S. globisporus wild-type strain as a control (I), establishing CB02366 as a new C-1027 producer with a significantly higher C-1027 (solid diamonds) titer. Titers
for C-1027 chromoprotein production were estimated on the basis of the C-1027 chromophore as determined by HPLC analysis. The S. globisporus wild-type
strain produces ~5.5 mg/liter of the C-1027 chromophore, which translates to ~74mg/liter of the C-1027 chromoprotein (9). mAU,milli-absorbance units. (C)
The structures of C-1027 (solid diamonds) and its aromatized metabolite (open diamonds).
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the gene cluster for UCM, discovered from S. uncialis (31), had
not been cloned until now. Thus, we first identified the ucm gene
cluster by sequencing the S. uncialis genome (Fig. 5A and Ta-
ble S3) and inactivated the ucmE gene in S. uncialis to generate
ucmEmutant strain SB18001 (Fig. S3 andTable S1). HPLC anal-
ysis of SB18001 fermentation, with the S. uncialis wild type as a
control, showed complete abolishment of UCMproduction, con-
firming that the cloned gene cluster encodes UCM biosynthesis
(Fig. 5C). We next identified the new enediyne gene cluster (i.e.,
the tnm cluster) from Streptomyces sp. strain CB03234 by genome
sequencing (Fig. 5A). Remarkably, while the dyn, ucm, and tnm
clusters show little conservation in genetic organization beyond
the enediyne PKS cassette (Fig. 5A), GNN analysis revealed that
the three clusters share many homologous genes (Fig. 5B; also see
Table S3) andmay therefore encode the biosynthesis of a common
enediyne core with various peripheral moieties.
To discover the new enediyne from Streptomyces sp. strain
CB03234, we first inactivated the tnmE gene in Streptomyces sp.
strain CB03234 to afford the correspondingtnmEmutant strain
SB20001 (Fig. S3 and Table S1). Comparison of the HPLCmetab-
olite profiles between fermentations of the Streptomyces sp.
CB03234 wild-type and SB20001mutant strains revealed onema-
jor metabolite whose biosynthesis could be readily correlated to
the tnm gene cluster (Fig. 5D). This metabolite was subsequently
isolated and named TNM A. The structure of TNM A was estab-
lished on the basis of extensive mass spectrometry (MS) and one-
dimensional (1D) and 2D nuclear magnetic resonance (NMR)
analysis (Fig. 6A and B; see also Fig. S4 and Table S5), with its
absolute stereochemistry established by comparison of the circu-
lar dichroism (CD) spectra of TNMA to an authentic UCM stan-
dard (Fig. 6C). TNM A featured an anthraquinone-fused 10-
membered enediyne core, characteristic of both DYN and UCM.
The DYN producer, isolated from a soil sample collected in Guja-
rat state, India, was identified as a M. chersina species (33). The
UCM producer, extracted from the surface of a lichen specimen
collected in British Columbia, Canada, was classified as a S. uncia-
lis species (31). Streptomyces sp. strain CB03234 was isolated from
a soil sample collected in Yuanjiang county, Yunnan Province,
China, and has been assigned as a Streptomyces venezuelae species
(Table S2). Pairwise comparison of the dyn, ucm, and tnm clusters,
as exemplified by the translated products of the enediyne PKS
cassette (i.e., E10/E/E5/E4/E3; Fig. 5A), revealed only 41% to 60%
amino acid sequence identity. It is therefore fascinating that three
distantly related strains, harboring gene clusters with distinct or-
ganizations, biosynthesize structurally related enediynes, indica-
tive of an intricate evolution for these complex natural-product
biosynthetic machineries.
FIG 4 An enediyne GNN revealing that the enediyne biosynthetic gene clusters discovered are rich in new chemistry and diverse structures. (A) The enediyne
GNN consisting of the known and new enediyne gene clusters (see Fig. 2B and C) displayed with an E value threshold of 106. The enediyne GNN displays both
the conserved nature and the diverse nature of proteins involved in enediyne biosynthesis. (B) The E2, E3, and R3 families displayed with an E value threshold
of 1075 to separate the E2 and E3 subfamilies for use as 9-membered versus 10-membered enediyne prediction. (C) Selected representatives of proteins of
unknown function, highlighting the vast number of uncharacterized and unknown chemistries found in enediyne biosynthesis. (D) Selected representatives of
proteins of unknown function found only in the new enediyne gene clusters, representing novel chemistry, enzymology, and structures found in the new
enediyne producers. Big and small dots and diamonds in panels A toDdenote known and predicted 9- and 10-membered enediynes, respectively. (E) A predicted
9-membered enediyne cluster from CB03578 (denoted by big dots) featuring tryptophan degradation enzymes with corresponding activation and condensing
enzymes, uncharacterized protein families, and singletons. (F) A predicted 10-membered enediyne cluster from CB03911 (denoted with big diamonds), with
several conserved families of proteins for regulation and resistance in 10-membered biosynthesis and shikimate pathway enzymes and singletons unique to
10-membered enediyne biosynthesis.
Yan et al.
















Manipulation of TNM biosynthesis in Streptomyces sp.
strain CB03234 demonstrating the feasibility of analogue engi-
neering.Microbial genome mining and metabolic pathway engi-
neering are rapidly changing the landscape of discovery and struc-
tural diversity of natural products (1, 28–30, 34, 35).Development
of an expedient genetic system for in vivo manipulation of the
targeted biosynthetic machinery is of paramount importance to
implement these emerging strategies. Thus, a critical decision in
manipulating enediyne biosynthesis is the selection of the produc-
ers that are compatible with the expedient technologies and tools
of recombinant DNA work in Streptomyces species and related
organisms that have been developed in the past two decades (1, 28,
34, 36, 37). Accordingly, the TSRI actinomycetes collection is en-
riched with Streptomyces species (Fig. 1E), and this selection is
vital to overcoming the current challenges of, and meeting future
objectives for, enediyne discovery, biosynthesis, and engineering
in their native producers.
We have developed an expedient genetic system for Streptomy-
ces sp. strain CB03234. The feasibility of manipulating TNM bio-
synthesis in Streptomyces sp. strain CB03234 to generate novel
analogues has been demonstrated by the engineered production
of a TNM analogue. Thus, we inactivated the tnmH gene, encod-
ing a putative O-methyltransferase (Fig. 5A and B and Table S3),
to generatetnmHmutant strain SB20002 (Fig. S3 and Table S1).
HPLC analysis of SB20002 fermentation, with the Streptomyces sp.
strain CB03234 wild type as a control, showed complete abolish-
ment of TNMAproduction and a concomitant accumulation of a
new metabolite (Fig. 5D), which was subsequently identified as
TNM C on the basis of extensive MS, CD, and 1D and 2D NMR
analysis (Fig. 6; see also Fig. S4 and Table S5). TNM C featured
an -OH group at C-7, as would be expected from inactivating
the tnmH gene, but an additional side chain at C-26, revealing
new insights into TNM A biosynthesis. Thus, TnmH-catalyzed
O-methylation at C-7 most likely takes place early in TNM A
biosynthesis, without which the side chain at C-26 cannot be fully
processed en route to TNMA as has been proposed previously for
UCM biosynthesis (31). Given the biosynthetic relationship
among DYN, TNM, and UCM (Fig. 5A and B), manipulation of
TNM biosynthesis in CB03234 therefore provides an outstanding
bioengineering platform to access the DYN and UCM scaffolds,
which have been difficult to access in their native producers due to
either recalcitrance to geneticmanipulation (for DYN) (16) or the
inability to produce in submerged fermentation (for UCM) (31).
TNMs exhibiting potent cytotoxicity, with rapid and com-
plete killing, toward a broad spectrum of cancer cell lines. The
enediynes are among themost cytotoxicmolecules known to date,
and they are active in many tumor types. Although the natural
enediynes have limited use as clinical drugs, both polymer-based
delivery systems and ADCs have shown great clinical success or
promise in anticancer therapy (3, 7). For example, poly(styrene-
comaleic acid)-conjugated NCS (SMANCS) has been marketed
since 1994 for use against hepatoma (38). Several ADCs have been
developed, including an anti-CD33monoclonal antibody (MAb)-
CAL conjugate (i.e., gemtuzumab ozogamicin) for acute myeloid
FIG 5 Characterization of Streptomyces sp. strain CB03234 as a TNM producer. (A) Genetic organization of the ucm, tnm, and dyn gene clusters (see Table S3).
Genes are color-coded based on GNN annotation (see Fig. 4). (B) GNN analysis (E value of 106) unveiling functional similarity among the dyn, ucm, and tnm
biosynthetic gene clusters. (C) HPLC analysis of fermentations of the S. uncialis wild-type strain (I) and SB18001 (i.e., ucmE) mutant (II), in comparison with
an authentic UCM standard (III), establishing the cloned gene cluster encoding UCM (solid circles) biosynthesis. (D) HPLC analysis of fermentations of the
Streptomyces sp. strain CB03234 wild type (I) and the SB20001 (i.e., tnmE) (II) and SB20002 (i.e., tnmH) (III) mutants, establishing the cloned gene cluster
encoding TNM A (solid diamond) biosynthesis and demonstrating the feasibility of manipulating TNM biosynthesis in Streptomyces sp. strain CB03234 as
exemplified by the engineered production of TNM C (inverted triangle) from SB20002.
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leukemia (AML) and an anti-CD22 MAb-CAL conjugate (inotu-
zumab ozogamicin) for non-Hodgkin lymphoma (39, 40), as well
as several MAb-C-1027 conjugates for hepatoma (24) and MAb-
UCM conjugates for selected tumors (N. S. Chowdari, S. Gang-
war, and B. Sufi, 22 August 2013, European patent application
WO 2013122823 A1). These examples demonstrate that the
enediynes can be developed into powerful drugs and that the new
enediynes therefore represent outstanding payload candidates for
ADCs.
We carried out preliminary cytotoxicity evaluations of TNMs
in comparison with UCM, auristatin F phenylenediamine (AFP)
(41), a variant of the natural product dolostatin 10, andmaytansi-
noid AP-3 (Fig. S1C). Auristatins and maytansinoids are used in
the FDA-approved ADCs brentuximab vedotin (Adcetris) and
trastuzumab emtansine (Kadcyla), respectively, as well as inmany
ADCs currently in clinical development (39, 40, 42, 43). The
TNMs are extremely potent against a broad spectrum of cancer
cell lines, with subnanomolar 50% inhibitory concentrations
(IC50s). For example, TNMA is more potent than UCM, particu-
larly against breast cancer cell lines (Table 1A); UCM is currently
in preclinical development as an ADC (Chowdari et al., European
patent application WO 2013122823 A1) (44). Most impressively,
as exemplified with the SKBR-3 breast cancer cell line, TNM A
exhibitedmore rapid andmore complete cell killing thanAFP and
AP-3 (Tables 1B and C), thereby minimizing the development of
potential drug resistance (45, 46), supporting the wisdom of ex-
ploiting the TNMs as payload candidates for the next generation
of anticancer ADCs.
Conclusions and significance. In spite of their profound im-
pact on modern chemistry, biology, and medicine, the enediyne
family of natural products remains very small, with only 11mem-
bers structurally characterized to date. Recent advances in DNA
sequencing and microbial genomics, however, clearly revealed
that the biosynthetic potential of soil actinomycetes to produce
enediynes is greatly underappreciated. A great challenge is that
of developing innovative methods to discover new enediynes
and producing them in sufficient quantities for chemical, bio-
logical, and clinical investigations. We recently reported a
high-throughput real-time PCR method to prioritize strains for
natural-product discovery. By adapting this method to identify
strains that are highly likely to encode enediyne biosynthesis, fol-
lowed by genome sequencing, bioinformatics analysis, genetic
manipulation, and fermentation optimization, we have nowdem-
onstrated the feasibility of rapid discovery of new enediynes from
a large strain collection. The new C-1027 producers, with a signif-
icantly higher C-1027 titer than the original producer, will impact
the practical supply of the drug should it eventually be brought
into clinical applications. The TNMs, with their extremely potent
cytotoxicity against a broad spectrumof cancer cells and rapid and
complete cell killing characteristics, in comparison with the pay-
FIG 6 Structural elucidation of TNM A and C on the basis of 1D and 2D NMR and CD spectroscopic data analysis. (A) Structures of TNM A and C in
comparison with that of UCM. (B) Key 1H-1H correlation spectroscopy (COSY), nuclear Overhauser effect spectroscopy (NOESY), and heteronuclear multiple
bond correlation (HMBC) analysis of TNMA andC, supporting their structural assignments (also see Table S4). (C) CD spectra of TNMA andC in comparison
with an authentic standard of UCM, supporting their absolute stereochemistry assignment.
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loads used in FDA-approved ADCs and ADCs in various stages of
development, are poised to be exploited as payload candidates for
the next generation of anticancer ADCs. Follow-up studies on the
other hits that have already been identified in this study or on
application of our strategy to other strain collections promise the
discovery of new enediynes, radically expanding the chemical
space for the enediyne family of natural products. Our results also
support strain prioritization and genomemining for the discovery
of other classes of natural products from ever-growing microbial
strain collections. Together with other emerging strategies and
technologies, these findings will inspire continued innovations in
natural-product discovery.
MATERIALS AND METHODS
General materials. Primers, plasmids, and strains used and reported in
this study are summarized in Table S1 in the supplemental material.
Construction of the actinomycetes genomic DNA library.Genomic
DNA (gDNA) was prepared from strains isolated from various unex-
plored and underexplored ecological niches (23, 47, 48). Strains were
cultivated in a rich liquid medium (tryptic soy broth [TSB]) for 2 to
3 days. DNA was isolated using the salting-out protocol (36), deposited
into 96-well plates, and stored at80°C.
Real-time PCR screening of 3,400 strains for enediyne producers.
Real-time PCR was performed using an Applied Biosystems 7900HT Fast
real-time PCR system. Preparation of gDNA arrays and application of
the real-time PCR method to survey the 3,400 actinomycetes strains for
the enediyne PKS gene cassette and to identify new enediyne producers
followed the published protocol for strain prioritization with modifica-
tions (23). For further details, see Text S1 in the supplemental material.
Genome sequencing and assembly. Genome sequencing of the rep-
resentative enediyne producers was performed using an Illumina MiSeq
sequencer (2  300 paired-end sequencing) at the Next Generation Se-
quencing and Microarray Core Facility, TSRI. Read quality filtering was
performed using a tool developed in-house. Adapter trimming and de
novo assembly were done with CLC Genomics Workbench version 7.5.1
(CLC Bio.) using default settings. The resulting contigs were further ex-
tended and joined into a final scaffold by SSPACE version 2.0 (49) using
all quality-filtered reads. The remaining gaps inside the final scaffold were
partially or completely filled using the quality-filtered reads by GapFiller
version 1.10 (50). The draft genome sequences of the selected hits (under
BioProject PRJNA293172) and S. uncialis DCA2648 (under BioProject
PRJNA286672) reported in this study have been deposited in GenBank,
with their accession numbers summarized in Table S2.
Enediyne genome neighborhood network (GNN).Annotation of the
new enediyne gene clusters and construction of the enediyne GNN were
carried out as described previously (5, 6). Annotations of all the enediyne
biosynthetic gene clusters reported in this study are summarized in Ta-
bles S3 and S4. The C-1027 gene cluster from Streptomyces sp. strain
CB02366, the ucm gene cluster from S. uncialis DCA2648, and the tnm
gene cluster from Streptomyces sp. strain CB03234 were deposited in
GenBank under accession numbers KU597647, KT762610, and
KT716443, respectively. Accession numbers for the other new enediyne
gene clusters are listed in Table S2.
The enediyne GNN was constructed and included (i) the 7 known
9-membered enediyne gene clusters (encoding C-1027, NCS,MDP, KED,
TABLE 1 Cytotoxicity of and killing of SKBR-3 cells by TNM Aa
a (A) Cytotoxicity of TNM A against selected breast and other cancer cell lines in comparison to UCM. (B)
Rapid and (C) complete killing of SKBR-3 cells by TNM A (red diamonds) in comparison with AFP (green
triangles) and AP-3 (blue squares) (see Fig. S1 for structures), analogues of the natural products auristatin and
maytansine used as payloads in the FDA-approved ADCs brentuximab vedotin (Adcetris) and trastuzumab
emtansine (Kadcyla), respectively. Each point represents the mean SD of results from at least three replicates,
and the IC50s were determined by computerized curve fitting using GraphPad Prism. ADC, antibody-drug
conjugates; TNM, tiancimycin; UCM, uncialamycin.
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SPO, CYA, and CYN), (ii) the 3 known 10-membered enediyne gene
clusters (encoding CAL, DYN, and ESP), (iii) the newly characterized
gene cluster for the 10-membered enediyne UCM, and (iv) the 31 new
enediyne gene clusters (i.e., the 28 distinct gene clusters plus the 3 homol-
ogous gene clusters from the same clade of CB00072) discovered in this
study (Fig. 2). Cytoscape v 3.0 was used for GNN generation, visualiza-
tion, and analysis (51). All GNNs were displayed using the “organic”
layout with edge widths corresponding to the E value corresponding to
comparisons between proteins. Amore detailed description is provided in
Text S1.
Gene inactivation. Inactivation of selected genes within the cloned
enediyne clusters in Streptomyces species was performed by gene replace-
ment following literature procedures (36, 37). The genotypes of the resul-
tant mutants were confirmed by PCR (Table S1) and Southern analysis
(Fig. S3) as described in Text S1.
Fermentation,production, andHPLCanalysesofC-1027.TheStrep-
tomyces sp. strain CB02366 wild-type and SB1036 (i.e., pksE) mutant
strains were cultured individually following previously reported proce-
dures (11), with the original C-1027 producer S. globisporus wild-type
strain as a control. The identity of C-1027 was confirmed by HPLC and
high-resolution electrospray ionization–mass spectrometry HR-ESI-MS
analysis (Fig. 3B) as described in Text S1. To determine C-1027 titers,
HPLC analysis was calibrated with an authentic C-1027 standard (9, 11).
Fermentation, production, and HPLC analysis of UCM. Fermenta-
tion of S. uncialis and production of UCM were performed on solid agar
medium (ISP4) following previously published procedures (31). The
identity of UCM was confirmed by HPLC and HR-ESI-MS analysis with
an authentic UCM standard (Fig. 5C) as described in Text S1.
Fermentation,production, andHPLCanalysesofTNMAandC.The
Streptomyces sp. strain CB03234 wild-type, SB20001 (i.e., tnmE), and
SB20002 (i.e., tnmH) mutant strains were cultured individually in
250-ml baffled flasks containing 50 ml of TSB liquid medium. After
growth at 28°C and 250 rpm for 2 days, 5ml of seed culturewas inoculated
into 250-ml baffled flasks containing 50 ml of the production medium
(1% soluble starch, 0.5% Pharmamedia, 0.2% CaCO3, 0.005% CuSO4·
5H2O, 0.0005% NaI, pH 7.0). The resulting cultures were incubated at
28°C and 250 rpm for 7 days and individually harvested. Each culture was
centrifuged, the supernatant was extracted with EtOAc, and the cell pellet
was extracted with CH3COCH3. The combined extracts were concen-
trated in vacuum and dissolved in CH3OH for HPLC and HR-ESI-MS
analysis (Fig. 5D) as described in Text S1. TNM titers were determined by
HPLC analysis calibrated with authentic standards.
Isolation and structural elucidation of TNMA and C. For structural
elucidation, TNM A (1.2 mg) was isolated from 6 liters of fermentation
culture of the Streptomyces sp. CB03234 wild-type strain, while TNM C
(0.7 mg) was isolated from 6 liters of fermentation culture of the tnmH
mutant strain SB20002. The structures of TNM A and C were established
on the basis of extensiveMS, CD, andNMR analysis (Fig. 6 and Table S2).
For further details, see Text S1.
Cytotoxicity assay of TNMs. The IC50s of TNMs against selected hu-
man cancer cell lines, including breast (MDA-MB-468, MDA-MB-231,
SKBR-3, KPL-4, BT474, and DYT2), melanoma (M14 and SK-MEL-5),
non-small cell lung cancer (NCI-H226), and central nervous system (SF-
295 and SF-539) cells, withUCMas a control, were determined by follow-
ing standard protocols described previously (47). Each point represents
the mean standard deviation (SD) of results from three replicates, and
the IC50 was determined by computerized curve fitting using GraphPad
Prism (Table 1A). For comparison of the cell killing rates among TNMA,
AFP, and AP-3, SK-BR-3 breast cancer cells were incubated with graded
doses (ranging from0 to 100nM)of drugs for 8, 12, 24, and 72 h before the
assays were developed as described above. Cell viability was expressed as a
percentage of the level seenwith untreated control cells (Tables 1B andC).
Further details are provided in Text S1.
Accession number(s).Accession numbers for the C-1027 gene cluster
from Streptomyces sp. strain CB02366, the ucm gene cluster from S. un-
cialis DCA2648, and the tnm gene cluster from Streptomyces sp. strain
CB03234 are KU597647, KT762610, and KT716443, respectively. Acces-
sion numbers for the draft genomes of the selected 31 hits, as well as the
UCM producer S. uncialis DCA2648, are summarized in Table S2.
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